 RALEIGH, NC ACCESSWIRE June 29, 2020 9 Meters Biopharma, Inc. NMTR, a clinical-stage rare and unmet needs-focused gastroenterology company, today announced that, after consultation with the FDA, the company will modify its definition of the primary endpoint in the ongoing Phase 3 trial evaluating larazotide for treating celiac disease. The validated instrument used for the primary assessment remains the Celiac Disease Patient-Reported Outcome CeD PRO. 